Recombinant ErbB2/Her2 (Trastuzumab Biosimilar) antibody
(1 reference)-
- Target See all ErbB2/Her2 (Trastuzumab Biosimilar) products
- ErbB2/Her2 (Trastuzumab Biosimilar)
- Antibody Type
- Recombinant Antibody
- Reactivity
- Human
-
Host
-
Human
-
Clonality
- Monoclonal
-
Conjugate
- This ErbB2/Her2 (Trastuzumab Biosimilar) antibody is un-conjugated
-
Application
- Flow Cytometry (FACS), ELISA, Immunohistochemistry (IHC)
- Specificity
- Oncogenic protein Her-2/neu (erbB-2), a member of the family of epidermal growth factor (EGF) receptors, overexpressed in 30 % of invasive breast cancers and 70 % of ductal carcinomata in situ, in a small percentage of melanomas, and in other malignancies originating from various organs, including ovary, kidney, colon, and bladder.
- Characteristics
-
OriginalSpeciesName: Human
OriginalFormat: IgG1
- Purification
- Purified antibody.
- Purity
- > 98 % as determined by SDS-PAGE
- Endotoxin Level
- Endotoxin is < 1.0 EU/mg as determined by the LAL method
- Immunogen
- A431 cells (human epidermoid carcinoma) (over)expressing EGFR.
- Clone
- 4D5-8
- Isotype
- IgG1 kappa
-
anti-ErbB2/Her2 (Trastuzumab Biosimilar) antibody
Research Grade Reactivity: Human FACS, ELISA Host: Humanized Monoclonal unconjugated Recombinant Antibody
anti-ErbB2/Her2 (Trastuzumab Biosimilar) antibodyReactivity: Human FACS, ELISA, IHC Host: Rabbit Monoclonal 4D5-8 unconjugated Recombinant Antibody
-
- Application Notes
- Optimal working dilution should be determined by the investigator.
- Comment
-
NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar.
- Restrictions
- For Research Use only
-
- Buffer
- PBS with 0.02 % Proclin 300.
- Preservative
- ProClin
- Precaution of Use
- This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
- Storage
- 4 °C,-20 °C
- Storage Comment
- Store at 4°C for up to 3 months. For longer storage, aliquot and store at -20°C.
-
-
: "Stapled EGFR peptide reduces inflammatory breast cancer and inhibits additional HER-driven models of cancer." in: Journal of translational medicine, Vol. 17, Issue 1, pp. 201, (2020) (PubMed).
-
: "Stapled EGFR peptide reduces inflammatory breast cancer and inhibits additional HER-driven models of cancer." in: Journal of translational medicine, Vol. 17, Issue 1, pp. 201, (2020) (PubMed).
-
- Target
- ErbB2/Her2 (Trastuzumab Biosimilar)
- Abstract
- ErbB2/Her2 (Trastuzumab Biosimilar) Products
- Synonyms
- CD340 antibody, HER-2 antibody, HER-2/neu antibody, HER2 antibody, MLN 19 antibody, NEU antibody, NGL antibody, TKR1 antibody, erb-b2 receptor tyrosine kinase 2 antibody, ERBB2 antibody
- Target Type
- Biosimilar
- Background
- CD340, Metastatic lymph node gene 19 protein (MLN 19), Proto-oncogene Neu, Proto-oncogene c-ErbB-2, Tyrosine kinase-type cell surface receptor HER2, p185erbB2, p185HER2, EGFR
- UniProt
- P04626
-
